Treating liver metastases in colorectal cancer

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma

Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF

Discussing the patient experience

Symptom management and combating side effects

Circulating metastasis-initiating cells in breast cancer

Bevacizumab benefits beyond progression in TML study subgroups

The immuno side of melanoma

Use of mesenchymal stromal cells against graft-versus-host disease

Next generation sequencing and the monoclonal structure of multiple myeloma

Assessing iron overload and toxicity